An affiliate company of DFB Pharmaceuticals Inc, Healthpoint, Ltd., has signed an exclusive agreement with IsoTis, S.A. to develop and license its patented, biologic, wound-healing technology called Allox.
The Weekly Roundup: September 23-27
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
LEO Pharma Presents Extensive Data at EADV
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations
Post Hoc Analysis of Vilobelimab in Hidradenitis Suppurativa Suggests Clinically Meaningful Benefits